"China is the largest manufacturer of chemical API in the market and exports API to 189 countries and regions in Asia, Europe, and North America. China has emerged as a leading global player in this sector due to several factors, including low production costs, a vast chemical manufacturing infrastructure, and a large pool of skilled labor. The country's API industry has experienced significant growth and development over the past few decades. Chinese API manufacturers, along with global stakeholders, are placing increased emphasis on diversifying supply chains, ensuring redundant capacities, and building robust contingency plans to mitigate future disruptions. Chinese API manufacturers are actively seeking collaborations and partnerships with international pharmaceutical companies, contract manufacturing organizations (CMOs), and research institutions. Chinese API manufacturers are recognizing this trend and are investing in biopharmaceutical capabilities, such as cell culture technologies and bioprocessing facilities, to cater to the increasing demand for these products. Data analytics, AI, and Internet of Things (IoT) technologies are being used by manufacturers to streamline production procedures, boost productivity, and ensure real-time monitoring and management of industrial activities. The use of nanotechnology in medication delivery systems is being investigated by Chinese API makers. The creation of cutting-edge pharmaceutical formulations now has more avenues for growth thanks to this invention. According to the report titled ""China Active Pharmaceutical Ingredients Market Overview, 2027"", published by Bonafide Research, the market is expected to grow exorbitantly over the forecast period. Though synthetic APIs are widely used to manufacture drugs, biotech APIs are expected to grow rapidly over the forecast period. This is due to the launches of new drugs and biological products, acquisitions, collaborations, and regional expansion initiatives being taken by the companies to maintain stability in the market. The captive segment has the largest market share and is anticipated to grow in the future owing to the easy availability of raw materials and huge investments by major companies to develop high-end manufacturing facilities. Recent advancements and research suggest that companies are more focused on in-house manufacturing than outsourcing to others. The captive API segment accounted for the major market share and is expected to grow at a steady CAGR over the forecast period. Generic APIs are expected to be in demand over the forecast period as the branded API segment's demands are declining. This is due to the consolidation in the pharma industry and various drugs going off-patent. Due to a rise in over-the-counter drugs and the lower cost of generic drugs, it is expected to lure consumers. The increasing obesity, diabetes, and other chronic diseases, which are long-lasting and require the patient to consume the drugs on a daily basis, drive the demand for cheaper alternatives to save costs. Thus, the demand for generic API will rise in future years coupled with government incentives.
Asia-Pacific dominates the market and is the largest and fastest-growing market in the animal growth promoters industry globallyDownload Sample
The cardiovascular diseases segment accounts for the largest application due to increasing heart-related diseases worldwide. Rising awareness, preventive treatment, and government measures are further expected to drive future demand for API. On the other hand, oncology applications are expected to grow rapidly over the forecast period due to the changing lifestyles of Millennials and the growing number of cancer patients in recent years. The metabolic disorders caused by sedentary lifestyles and hormonal imbalances created in the human body are the factors increasing the risks of these diseases. Diabetes is another chronic disease that is on the rise among the populace in the country. Though synthetic APIs led the market, biotech APIs are expected to grow rapidly in the forecast period owing to increased demand for biopharmaceuticals and the number of innovations in the field to meet medical needs for various diseases. It is considered to be a highly profitable segment that has attracted many key players to invest in these manufacturing facilities. The FDA approvals for vaccines, blood components, and recombinant proteins are further expected to boost market growth. Many companies are now focusing exclusively on producing biological drugs as it is a lucrative market. COVID-19 Impact: The pandemic had a combination of effects on the API market, creating demand shocks across the world, but some drugs that were required to treat the virus' effects were in huge demand. There was an increased demand for fever, cold, and cough drugs. In 2020 it decreased by -2.80% due to supply chain logistics which were at a standstill. However, the future markets are projected to grow exorbitantly as they have recovered from the pandemic shocks. Many manufacturing units in China were shut down due to a lack of raw materials and the pandemic effects which affected the world markets for API. Also, the decrease in demand for pharmaceuticals for certain elective procedures has also led to a decline in the market's growth in 2020. The sales declined also because the supply chain logistics were at a standstill due to immobility. Although the demand for drugs like paracetamol, azithromycin, and hydroxychloroquine is up, the demand for them is down. To treat the symptoms and numerous health conditions that a COVID-19 patient may have, such as cough, cold, and high fever, a variety of medications are employed, leading to the pharmaceutical industry being the epicenter of the pandemic. API manufacturers in China are pursuing to meet the growing demand for pharmaceutical products. The industry continues to evolve and adapt to advancements in science, technology, and patient needs. API manufacturers are increasingly partnering with research institutions, startups, and other industry stakeholders to foster collaboration and open innovation. By sharing knowledge, resources, and expertise, they can accelerate the development of new ideas and bring innovative products to market more rapidly. API manufacturers are also using new technologies, such as artificial intelligence (AI) and machine learning, to improve their manufacturing processes. These technologies are used to optimize process parameters, predict yields, and identify potential problems Considered in this report ? Geography: United States (US) ? Historic Year: 2016 ? Base year: 2021 ? Estimated year: 2022 ? Forecast year: 2027
Aspects covered in this report United States • Active Pharmaceutical Ingredients Market with its value, forecast, and segments • Application wise Active Pharmaceutical Ingredients distribution • Various drivers and challenges • On-going trends and developments • Top profiled companies • Strategic recommendation Based on a synthesis of Active Pharmaceutical Ingredients in the report • Synthetic API • Biotech API Based on the drug type of Active Pharmaceutical Ingredients in the report • Branded API • Generic API
Based on the type of manufacture of Active Pharmaceutical Ingredients in the report • Captive API • Merchant API By Therapeutic Application Type in the report • Communicable Diseases • Oncology • Diabetes • Cardiovascular Disease • Pain management • Respiratory Diseases • Other Therapeutic Applications The approach of the report This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and list out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, annual reports of companies, and analyzing government-generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducting trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers in regional aspects, tier aspects, age group, and gender. Once we have primary data with us we have started verifying the details obtained from secondary sources. Intended audience This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to the pharmaceutical industry, government bodies, and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry. Please get in touch with our sales team to find out more."